Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEE011 versus placebo for relapsed or refractory progressive teratoma
NL-OMON41774Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in teratoma comparing Ribociclib with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Aug 2015; status: active, not recruiting.
02
Drugs
ribociclib
03
Conditions
teratoma
Beyond the preview
Go deeper on NL-OMON41774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41774.